secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001628280-26-030136
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Q1 product revenue $60.1M; IMCIVREE HO launch >150 start forms; net loss $(0.83)/share
--------------------------------------------------------------------------------

- Q1 2026 net product revenue $60.1M (up 5% sequentially); U.S. revenue $36.9M, ex-U.S. $23.2M.
- IMCIVREE received FDA approval for acquired hypothalamic obesity on Mar 19; >150 patient start forms in first six weeks.
- European Commission granted marketing authorization for IMCIVREE in acquired HO on May 1, 2026.
- Net loss $(56.7)M ($(0.83)/share) vs $(50.8)M ($(0.81)/share) in Q1 2025; cash $340.6M.
- Phase 3 EMANATE trial missed primary endpoint; positive post-hoc signals in SRC1 and POMC insufficiencies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026030136/0001628280-26-030136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026030136/rytm-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-030136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer